RECRUITING

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Description

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment

Conditions

Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract Cancer
Talk to us

Related Conditions:

Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract Cancer

Study Overview

On this page

Study Details

Study overview

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA ( Site 0317), Los Angeles, California, United States, 90095

Aurora

University of Colorado Anschutz Medical Campus ( Site 0299), Aurora, Colorado, United States, 80045

Denver

UCHealth Cherry Creek Medical Center ( Site 0326), Denver, Colorado, United States, 80206

Highlands Ranch

UCHealth Highlands Ranch Hospital ( Site 0325), Highlands Ranch, Colorado, United States, 80129

Washington

Sibley Memorial Hospital ( Site 0310), Washington, District of Columbia, United States, 20016

Gainesville

University of Florida College of Medicine ( Site 0281), Gainesville, Florida, United States, 32610

Miami Beach

Mount Sinai Cancer Center ( Site 0287), Miami Beach, Florida, United States, 33140

Marietta

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303), Marietta, Georgia, United States, 30060

Mineola

Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola, New York, United States, 11501

New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Has one of the following cancers:
  • * Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer
  • * Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer
  • * Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer
  • * Advanced and/or unresectable BTC and has not received prior therapy for the cancer
  • * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment
  • * History of severe eye disease
  • * For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
  • * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Merck Sharp & Dohme LLC,

Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC

Study Record Dates

2029-10-16